Osteoporosis Clinical Trial
Official title:
Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures?
Verified date | March 2023 |
Source | University of Bern |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Vertebroplasty itself is challenged regarding its clinical efficacy. While two randomized controlled trials (RCTs) with substantial methodological problems have led to an intense discussion another RCT with larger case numbers, more representative inclusion criteria and a more consistent and sound methodology has revealed results that mirror the investigators' own clinical experience. In their daily practice, the investigators have further advanced their treatment concept and routinely apply prophylactic augmentations with VP using an algorithm. Biomechanical studies support their approach, but clinical studies are rare so far. Prophylactic augmentation with balloon kyphoplasty has not shown convincing effects in a small pilot study. Given the above mentioned methodological and clinical disputes and the call for high-evidence studies about VP, the investigators aim at generating a reliable sample size calculation and preliminary results for a future multicenter RCT about prophylactic adjacent level augmentation with VP in single level osteoporotic compression fractures.
Status | Terminated |
Enrollment | 100 |
Est. completion date | February 2022 |
Est. primary completion date | February 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years and older |
Eligibility | Inclusion Criteria: - Age = 55 years - Written informed consent - Single level acute (< 6 weeks) vertebral compression fracture - Fracture due to diagnosed or presumed underlying primary or secondary osteoporosis - Patients with Association for the study of Osteosynthesis (AO) type A1.x fractures and A3.1 fractures may be included in the study - Target Vertebral Compression Fracture (VCF) is between T10 and L4 - Target VCF to be treated shows either: height change - an acute (< 6 weeks) change in VB height (>15% height loss) with height loss at the anterior or middle portion of the VB consistent with a worsening of 1 or more grades acc to Genant - OR positive MRI or bone scan - VB shows hyperintense signal on MRI-T2 or STIR sequence - OR target VB is positive on radionuclide bone scan - Back pain correlating with the location of the VCF - Treatment of target and adjacent VCFs is technically feasible by and clinically appropriate for vertebroplasty - No previous VCFs - No major surgery of the spine planned for at least 6 months following enrollment - Pre-treatment back pain by numerical rating scale (NRS) score > 4 (0-10 scale) - Subject is able to understand the risks and benefits of participating in the study and is willing to provide written informed consent - Psychosocially, mentally and physically able to fully comply with the protocol requirements for the duration of the study including adhering to scheduled visits, treatment plan, completing forms and other study procedures. Exclusion Criteria - VB morphology or configuration is such that vertebroplasty is not technically feasible for the targeted and adjacent VCFs - Fracture due to high-energy trauma - Suspected OR proven cancer inside index vertebral body - Disabling back pain due to causes other than acute fracture (e.g., sacroiliac fracture, symptomatic degenerative disc disease, lumbar spinal stenosis) - Any painful VCF with fracture age > 6 weeks - Patients with primary tumors of the bone (e.g., osteosarcoma) or solitary plasmacytoma at site of the index or adjacent VCF - Any objective evidence of neurologic compromise at baseline. - Previous balloon kyphoplasty, VBS or vertebroplasty for any VCF - Significant clinical comorbidity that may potentially interfere with follow-up (e.g., dementia, severe comorbid illness) - Patients requiring the use of high-dose steroid (>= 100mg prednisone or 20 mg dexamethasone per day), IV pain medication, or nerve block to control chronic back pain unrelated to index VCF - Spinal cord compression or canal compromise requiring decompression - Patients with osteoblastic tumors at the site of the index VCF - MRI contraindication (e.g. cerebral aneurysm clips, pacemaker, implanted biostimulators, cochlear implants, penile prosthesis) - Spinal instability as indicated by neurologic deficit, kyphosis >30°, compression >50%, translation >4 mm, interspinous-process widening. - Pre-existing conditions contrary to vertebroplasty, such as: irreversible coagulopathy or bleeding disorder - Allergy to bone cement. - Any evidence of VB or systemic infection |
Country | Name | City | State |
---|---|---|---|
Switzerland | Sonnenhof hospital, dept. of spinal surgery | Bern |
Lead Sponsor | Collaborator |
---|---|
University of Bern | Sonnenhof Hospital, Bern |
Switzerland,
Diel P, Freiburghaus L, Roder C, Benneker LM, Popp A, Perler G, Heini PF. Safety, effectiveness and predictors for early reoperation in therapeutic and prophylactic vertebroplasty: short-term results of a prospective case series of patients with osteoporo — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of new operations within 6 months after vertebroplasty due to adjacent or distant segment fracture. | Measured by interview, clinical & radiographic assessment | 6 months after index surgery | |
Secondary | Disease specific quality of life (COMI back form) | Measured by questionnaire | 6 months after index surgery | |
Secondary | General quality of life | Measured by questionnaire | 6 months after index surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06287502 -
Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis
|
N/A | |
Completed |
NCT03822078 -
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
|
Phase 1 | |
Recruiting |
NCT05845021 -
Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04736693 -
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
|
||
Not yet recruiting |
NCT06431867 -
Primary Care Management of Osteoporosis in Older Women
|
||
Completed |
NCT02922478 -
Role of Comorbidities in Chronic Heart Failure Study
|
||
Recruiting |
NCT02635022 -
Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
|
||
Recruiting |
NCT02616627 -
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
|
||
Active, not recruiting |
NCT02617303 -
Prevention of Falls and Its Consequences in Elderly People
|
N/A | |
Completed |
NCT02566655 -
Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis
|
Phase 1 | |
Completed |
NCT03420716 -
Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women
|
N/A | |
Not yet recruiting |
NCT02223572 -
Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
|
N/A | |
Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
Unknown status |
NCT01913834 -
Nasally and sc Administered Teriparatide in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT01854086 -
Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday
|
N/A | |
Completed |
NCT02003716 -
DeFRA Questionnaire as an Anamnestic Form
|
N/A | |
Completed |
NCT01401556 -
C-STOP Fracture Trial
|
N/A | |
Completed |
NCT01694784 -
Understanding and Discouraging Overuse of Potentially Harmful Screening Tests
|
N/A |